rapamycin

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酯内酰胺
• 英文名称: rapamycin
• 英文别名: (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30R,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
• 化学式: C₅₁H₇₉NO₁₃
• 分子量: 914.187
• InChiKey: QFJCIRLUMZQUOT-RIPNRHRMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  65
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  195
• 氢给体数：
  3
• 氢受体数：
  13

反应信息

• 作为产物：
  描述：

  雷帕霉素 在 三氟乙酸 作用下， 以 甲醇 为溶剂， 生成 rapamycin
  参考文献：
  名称：

  Manipulation of the Rapamycin Effector Domain. Selective Nucleophilic Substitution of the C7 Methoxy Group

  摘要：

  The C-7 methoxy group in rapamycin has been found to be labile toward acidic reagents. Conditions have been developed to replace this group with a number of different nucleophiles, such as alcohols, thiols, and electron-rich aromatic systems. This novel, efficient transformation allows the selective manipulation of the rapamycin effector domain.

  DOI：

  10.1021/jo00101a006

文献信息

• Aie luminogens for visualization and treatment of cancer
  申请人：THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY

  公开号：US10935552B2

  公开（公告）日：2021-03-02

  The present subject matter relates to ATE luminogens for visualization and treatment of cancer, particularly AIE luminogenic probes for cancer cell visualization and discrimination, lysosome-targeting AIEgens for imaging and autophagy visualization, highly fluorescent AIE-active theranostic agents for monitoring drug distribution and having anti-tumor activity to specific cancer cells, probes comprising AIE luminogens for cancer cell imaging and staining, AIE luminogens having clusteroluminogenic features and applications thereof, and methods of preparing thereof.

  本主题涉及用于癌症可视化和治疗的 ATE 发光剂，特别是用于癌细胞可视化和鉴别的 AIE 发光探针、用于成像和自噬可视化的溶酶体靶向 AIE 发光剂、用于监测药物分布并对特定癌细胞具有抗肿瘤活性的高荧光 AIE 活性治疗剂、包含用于癌细胞成像和染色的 AIE 发光剂的探针、具有簇发光特性的 AIE 发光剂及其应用，以及其制备方法。
• THERAPEUTIC AGENT FOR MEIBOMIAN GLAND DYSFUNCTION
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：US20160022648A1

  公开（公告）日：2016-01-28

  A compound represented by the formula (1): wherein R 1 represents a hydroxyl group, a dimethylphosphynoyloxy group, etc.; and R 2 and R 3 represent a methoxy group, etc., or a pharmaceutically acceptable salt thereof can reduce a score of telangiectasia around the meibomian gland orifices and a number of obstruction at the orifices, so that it is useful as a prophylactic and/or therapeutic agent for meibomian gland dysfunction.
• THERAPEUTIC AGENT FOR MEIBOMIAN DYSFUNCTION
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：US20180021314A1

  公开（公告）日：2018-01-25

  A method for treatment of meibomian gland dysfunction in a mammalian subject, the method involving administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to the eyes of the mammalian subject 1 to 2 times per day.
• AIE LUMINOGENS FOR VISUALIZATION AND TREATMENT OF CANCER
  申请人：THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY

  公开号：US20180156811A1

  公开（公告）日：2018-06-07

  The present subject matter relates to ATE luminogens for visualization and treatment of cancer, particularly AIE luminogenic probes for cancer cell visualization and discrimination, lysosome-targeting AIEgens for imaging and autophagy visualization, highly fluorescent AIE-active theranostic agents for monitoring drug distribution and having anti-tumor activity to specific cancer cells, probes comprising AIE luminogens for cancer cell imaging and staining, AIE luminogens having clusteroluminogenic features and applications thereof, and methods of preparing thereof.
• Manipulation of the Rapamycin Effector Domain. Selective Nucleophilic Substitution of the C7 Methoxy Group
  作者：Juan I. Luengo、Arda Konialian-Beck、Leonard W. Rozamus、Dennis A. Holt

  DOI：10.1021/jo00101a006

  日期：1994.11

  The C-7 methoxy group in rapamycin has been found to be labile toward acidic reagents. Conditions have been developed to replace this group with a number of different nucleophiles, such as alcohols, thiols, and electron-rich aromatic systems. This novel, efficient transformation allows the selective manipulation of the rapamycin effector domain.